Stevens-Johnson综合征/中毒性表皮坏死松解症诊疗专家共识

doi:10.35541/cjd.20201177

Abstract

Abstract: 【Abstract】 Stevens-Johnson syndrome （SJS）/toxic epidermal necrolysis （TEN） is a severe cutaneous-mucosal response that carries a high risk of death, mostly induced by drugs, characterized by blisters and generalized epidermolysis, accompanied by a series of systemic symptoms, including multiple organ dysfunction syndrome. Based on the latest domestic and international consensus, guidelines and medical evidence, and combined with the current status of the diagnosis and treatment of SJS/TEN in China, the Adverse Drug Reaction Research Center of Chinese Society of Dermatology organized relevant experts to develop this consensus on SJS/TEN in terms of the definition, etiology, pathogenesis, clinical characteristics, diagnosis, identification of culprit drugs, evaluation of disease progression, treatment, prevention and so on, aiming to provide a reference for clinicians in clinical practice.

Key words: Stevens-Johnson syndrome, Epidermal necrolysis, toxic, Drug eruptions, Drug toxicity, Expert consensus

Adverse Drug Reaction Research Center of Chinese Society of Dermatology. Expert consensus on the diagnosis and treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis[J].Chinese Journal of Dermatology, 2021, 54(5): 376-381.

References ［53］

［1］	White KD, Abe R, Ardern⁃Jones M, et al. SJS/TEN 2017: building multidisciplinary networks to drive science and translation［J］. J Allergy Clin Immunol Pract, 2018,6（1）:38⁃69. doi: 10.1016/j.jaip.2017.11.023.
［2］	Hsu DY, Brieva J, Silverberg NB, et al. Morbidity and mortality of Stevens⁃Johnson syndrome and toxic epidermal necrolysis in United States adults［J］. J Invest Dermatol, 2016,136（7）:1387⁃1397. doi: 10.1016/j.jid.2016.03.023.
［3］	马慧淼, 陈媚, 刘猛, 等. 纳武单抗导致Stevens⁃Johnson综合征1例［J］. 中国肿瘤临床, 2020,47（2）:105⁃106. doi: 10.3969/j.issn.1000⁃8179.2020.02.449.
［4］	Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens⁃Johnson syndrome［J］. Nature, 2004,428（6982）:486. doi: 10.1038/428486a.
［5］	Mallal S, Nolan D, Witt C, et al. Association between presence of HLA⁃B*5701, HLA⁃DR7, and HLA⁃DQ3 and hypersensitivity to HIV⁃1 reverse⁃transcriptase inhibitor abacavir［J］. Lancet, 2002,359（9308）:727⁃732. doi: 10.1016/s0140⁃6736（02）07873⁃x.
［6］	Hung SI, Chung WH, Liou LB, et al. HLA⁃B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol［J］. Proc Natl Acad Sci U S A, 2005,102（11）:4134⁃4139. doi: 10.1073/pnas.0409500102.
［7］	Yang F, Xuan J, Chen J, et al. HLA⁃B*59:01: a marker for Stevens⁃Johnson syndrome/toxic epidermal necrolysis caused by methazolamide in Han Chinese［J］. Pharmacogenomics J, 2016,16（1）:83⁃87. doi: 10.1038/tpj.2015.25.
［8］	Zhang FR, Liu H, Irwanto A, et al. HLA⁃B*13:01 and the dapsone hypersensitivity syndrome［J］. N Engl J Med, 2013,369（17）:1620⁃1628. doi: 10.1056/NEJMoa1213096.
［9］	Tangamornsuksan W, Lohitnavy M. Association between HLA⁃B*1301 and dapsone⁃induced cutaneous adverse drug reactions: a systematic review and meta⁃analysis［J］. JAMA Dermatol, 2018,154（4）:441⁃446. doi: 10.1001/jamadermatol.2017.6484.
［10］	Yang F, Gu B, Zhang L, et al. HLA⁃B*13:01 is associated with salazosulfapyridine⁃induced drug rash with eosinophilia and systemic symptoms in Chinese Han population［J］. Pharmacogenomics, 2014,15（11）:1461⁃1469. doi: 10.2217/pgs.14.69.
［11］	Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens⁃Johnson syndrome and toxic epidermal necrolysis［J］. Nat Med, 2008,14（12）:1343⁃1350. doi: 10.1038/nm.1884.
［12］	Viard⁃Leveugle I, Gaide O, Jankovic D, et al. TNF⁃α and IFN⁃γ are potential inducers of Fas⁃mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis［J］. J Invest Dermatol, 2013,133（2）:489⁃498. doi: 10.1038/jid.2012.330.
［13］	夏倩倩, 孙勇虎. Stevens⁃Johnson综合征/中毒性表皮坏死松解综合征的发病机制研究进展［J］. 中国皮肤性病学杂志, 2019,33（6）:713⁃716. doi: 10.13735/j.cjdv.1001⁃7089.201805125.
［14］	Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients［J］. Arch Dermatol, 1987,123（9）:1160⁃1165. doi: 10.1001/archderm.123. 9.1160.
［15］	Yang L, Shou YH, Li F, et al. Retrospective study of 213 cases of Stevens⁃Johnson syndrome and toxic epidermal necrolysis from China［J］. Burns, 2020,46（4）:959⁃969. doi: 10.1016/j.burns.2019.10.008.
［16］	Gao X, Tang X, Ai L, et al. Acute pancreatic injuries: a complication of Stevens⁃Johnson syndrome/toxic epidermal necrolysis associated with cytotoxic immunocell activation［J］. J Am Acad Dermatol, 2020,84（3）:644⁃653. doi: 10.1016/j.jaad. 2020.06.043.
［17］	Chen CB, Hsu TH, Chung⁃Yee Hui R, et al. Disseminated intravascular coagulation in Stevens⁃Johnson syndrome and toxic epidermal necrolysis［J/OL］. J Am Acad Dermatol, 2020:S0190⁃9622（20）32459⁃2［2021⁃02⁃26］. https://www.sciencedirect.com/science/article/pii/S0190962220324592?via%3Dihub. doi: 10.1016/j.jaad.2020.08.065.
［18］	Friedmann PS, Ardern⁃Jones M. Patch testing in drug allergy［J］. Curr Opin Allergy Clin Immunol, 2010,10（4）:291⁃296. doi: 10.1097/ACI.0b013e32833aa54d.
［19］	Hari Y, Frutig⁃Schnyder K, Hurni M, et al. T cell involvement in cutaneous drug eruptions［J］. Clin Exp Allergy, 2001,31（9）:1398⁃1408. doi: 10.1046/j.1365⁃2222.2001.01164.x.
［20］	Polak ME, Belgi G, McGuire C, et al. In vitro diagnostic assays are effective during the acute phase of delayed⁃type drug hypersensitivity reactions［J］. Br J Dermatol, 2013,168（3）:539⁃549. doi: 10.1111/bjd.12109.
［21］	You J, Sun L, Zhao Q, et al. Dynamic cytokine profiles combined with enzyme⁃linked immunospot assay are useful for immunologically confirming the dapsone hypersensitivity syndrome［J/OL］. J Am Acad Dermatol, 2020:S0190⁃9622（20）31093⁃8［2021⁃02⁃26］. https://www.sciencedirect.com/science/article/pii/S0190962220310938?via%3Dihub. doi: 10.1016/j.jaad. 2020.06.032.
［22］	Khan DA. Pharmacogenomics and adverse drug reactions: primetime and not ready for primetime tests［J］. J Allergy Clin Immunol, 2016,138（4）:943⁃955. doi: 10.1016/j.jaci.2016.08.002.
［23］	Bastuji⁃Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity⁃of⁃illness score for toxic epidermal necrolysis［J］. J Invest Dermatol, 2000,115（2）:149⁃153. doi: 10.1046/j.1523⁃1747.2000.00061.x.
［24］	Trent JT, Kirsner RS, Romanelli P, et al. Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States［J］. Arch Dermatol, 2004,140（7）:890⁃892. doi: 10.1001/archderm.140.7.890.
［25］	Micheletti RG, Chiesa⁃Fuxench Z, Noe MH, et al. Stevens⁃Johnson syndrome/toxic epidermal necrolysis: a multicenter retrospective study of 377 adult patients from the United States［J］. J Invest Dermatol, 2018,138（11）:2315⁃2321. doi: 10.1016/j.jid.2018.04.027.
［26］	Cartotto R, Mayich M, Nickerson D, et al. SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a burn center［J］. J Burn Care Res, 2008,29（1）:141⁃146. doi: 10.1097/BCR.0b013e31815f3865.
［27］	张松, 祁冬冬, 倪静, 等. Stevens⁃Johnson综合征及中毒性表皮坏死松解症48例临床资料分析［J］. 临床皮肤科杂志, 2019,48（11）:665⁃667. doi: 10.16761/j.cnki.1000⁃4963.2019.11. 005.
［28］	Pham TN, Cancio LC, Gibran NS, et al. American Burn Association practice guidelines burn shock resuscitation［J］. J Burn Care Res, 2008,29（1）:257⁃266. doi: 10.1097/BCR.0b013e 31815f3876.
［29］	Wang CW, Yang LY, Chen CB, et al. Randomized, controlled trial of TNF⁃α antagonist in CTL⁃mediated severe cutaneous adverse reactions［J］. J Clin Invest, 2018,128（3）:985⁃996. doi: 10.1172/JCI93349.
［30］	Liu W, Nie X, Zhang L. A retrospective analysis of Stevens⁃Johnson syndrome/toxic epidermal necrolysis treated with corticosteroids［J］. Int J Dermatol, 2016,55（12）:1408⁃1413. doi: 10.1111/ijd.13379.
［31］	Schneck J, Fagot JP, Sekula P, et al. Effects of treatments on the mortality of Stevens⁃Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study［J］. J Am Acad Dermatol, 2008,58（1）:33⁃40. doi: 10.1016/j.jaad.2007.08.039.
［32］	Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens⁃Johnson syndrome/toxic epidermal necrolysis［J］. Acta Derm Venereol, 2007,87（2）:144⁃148. doi: 10.2340/00015555⁃0214.
［33］	Hirahara K, Kano Y, Sato Y, et al. Methylprednisolone pulse therapy for Stevens⁃Johnson syndrome/toxic epidermal necrolysis: clinical evaluation and analysis of biomarkers［J］. J Am Acad Dermatol, 2013,69（3）:496⁃498. doi: 10.1016/j.jaad. 2013.04.007.
［34］	Kim KJ, Lee DP, Suh HS, et al. Toxic epidermal necrolysis: analysis of clinical course and SCORTEN⁃based comparison of mortality rate and treatment modalities in Korean patients［J］. Acta Derm Venereol, 2005,85（6）:497⁃502. doi: 10.1080/00015550510038232.
［35］	Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin［J］. Science, 1998,282（5388）:490⁃493. doi: 10.1126/science.282.5388.490.
［36］	Ye LP, Zhang C, Zhu QX. The effect of intravenous immunoglobulin combined with corticosteroid on the progression of Stevens⁃Johnson syndrome and toxic epidermal necrolysis: a meta⁃analysis［J］. PLoS One, 2016,11（11）:e0167120. doi: 10.1371/journal.pone.0167120.
［37］	Tsai TY, Huang IH, Chao YC, et al. Treating toxic epidermal necrolysis with systemic immunomodulating therapies: a systematic review and network meta⁃analysis［J］. J Am Acad Dermatol, 2021,84（2）:390⁃397. doi: 10.1016/j.jaad.2020.08.122.
［38］	Lee HY, Lim YL, Thirumoorthy T, et al. The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre［J］. Br J Dermatol, 2013,169（6）:1304⁃1309. doi: 10.1111/bjd.12607.
［39］	杨永生, 徐金华, 李锋, 等. 静脉注射丙种球蛋白和糖皮质激素治疗重症大疱性药疹65例［J］. 中华皮肤科杂志, 2009,42（5）:330⁃332. doi: 10.3760/cma.j.issn.0412⁃4030.2009.05.012.
［40］	陈金波, 王宝玺, 王宏伟, 等. Stevens⁃Johnson综合征及中毒性表皮坏死松解症61例回顾性分析［J］. 中华皮肤科杂志, 2008,41（8）:542⁃545.
［41］	Valeyrie⁃Allanore L, Wolkenstein P, Brochard L, et al. Open trial of ciclosporin treatment for Stevens⁃Johnson syndrome and toxic epidermal necrolysis［J］. Br J Dermatol, 2010,163（4）:847⁃853. doi: 10.1111/j.1365⁃2133.2010.09863.x.
［42］	Singh GK, Chatterjee M, Verma R. Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid［J］. Indian J Dermatol Venereol Leprol, 2013,79（5）:686⁃692. doi: 10.4103/0378⁃6323.116738.
［43］	Kirchhof MG, Miliszewski MA, Sikora S, et al. Retrospective review of Stevens⁃Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine［J］. J Am Acad Dermatol, 2014,71（5）:941⁃947. doi: 10.1016/j.jaad.2014.07.016.
［44］	Paradisi A, Abeni D, Bergamo F, et al. Etanercept therapy for toxic epidermal necrolysis［J］. J Am Acad Dermatol, 2014,71（2）:278⁃283. doi: 10.1016/j.jaad.2014.04.044.
［45］	陆晓君, 经晶, 施辛, 等. 重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗中毒性表皮坏死松解症的临床疗效观察［J］. 中华皮肤科杂志, 2020,53（6）:428⁃434. doi: 10.35541/cjd.2020 0068.
［46］	韩锋, 张静静, 侯彦丽, 等. 单纯单次血浆置换疗法治疗17例中毒性表皮坏死松解症临床观察［J］. 中华皮肤科杂志, 2018,51（12）:896⁃898. doi: 10.3760/cma.j.issn.0412⁃4030.2018.12. 010.
［47］	Yamane Y, Matsukura S, Watanabe Y, et al. Retrospective analysis of Stevens⁃Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients⁃⁃treatment and outcome［J］. Allergol Int, 2016,65（1）:74⁃81. doi: 10.1016/j.alit.2015.09.001.
［48］	陈娜娜, 张立明, 肖汀. Stevens⁃Johnson综合征的治疗及预后:38例回顾性分析［J］. 中国皮肤性病学杂志, 2016,30（8）:796⁃798. doi: 10.13735/j.cjdv.1001⁃7089.201603132.
［49］	张晓, 李冰, 王雷, 等. 注射用重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白联合甲泼尼龙治疗中毒性表皮坏死松解症5例［J］. 中国皮肤性病学杂志, 2020,34（9）:1018⁃1022. doi: 10.13735/j.cjdv.1001⁃7089.202002017.
［50］	Chen P, Lin JJ, Lu CS, et al. Carbamazepine⁃induced toxic effects and HLA⁃B*1502 screening in Taiwan［J］. N Engl J Med, 2011,364（12）:1126⁃1133. doi: 10.1056/NEJMoa1009717.
［51］	Ke CH, Chung WH, Wen YH, et al. Cost⁃effectiveness analysis for genotyping before allopurinol treatment to prevent severe cutaneous adverse drug reactions［J］. J Rheumatol, 2017,44（6）:835⁃843. doi: 10.3899/jrheum.151476.
［52］	Liu H, Wang Z, Bao F, et al. Evaluation of prospective HLA⁃B*13:01 screening to prevent dapsone hypersensitivity syndrome in patients with leprosy［J］. JAMA Dermatol, 2019,155（6）:666⁃672. doi: 10.1001/jamadermatol.2018.5360.
［53］	Wang CW, Tassaneeyakul W, Chen CB, et al. Whole genome sequencing identifies genetic variants associated with co⁃trimoxazole hypersensitivity in Asians［J/OL］. J Allergy Clin Immunol, 2020:S0091⁃6749（20）31109⁃X［2021⁃02⁃26］. https://www.sciencedirect.com/science/article/pii/S009167492031109X? via%3Dihub. doi: 10.1016/j.jaci.2020.08.003.

[1]	Kang Li, Liu Yan, Zheng Yunyan, Ju Mei, Zhang Yamei, Bi Zhigang, Lu Guiqing. Clinical analysis of cutaneous delayed-type hypersensitivity caused by injection of equine tetanus antitoxin or equine anti-tetanus immunoglobulin F（ab′）₂ [J]. Chinese Journal of Dermatology, 2021, 54(3): 226-228.
[2]	Deng Sisi, Wang Huan, Yu Nanlan, Li Song, Song Zhiqiang. Clinical analysis of 45 cases of drug-induced hypersensitivity syndrome [J]. Chinese Journal of Dermatology, 2021, 54(2): 127-130.
[3]	Pigmentary Disorder Group, Combination of Traditional and Western Medicine Dermatology. Consensus on the diagnosis and treatment of vitiligo （2021 version） [J]. Chinese Journal of Dermatology, 2021, 54(2): 105-109.
[4]	Wang Ruojun, Li Ruoyu. Adverse reactions to interleukin-17A and its receptor antagonists in the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2021, 54(2): 170-173.
[5]	Da Meihong, Shi Meiqi, Yan Qiao, Yang Haijing, Dong Zhengbang, Wang Fei. Skin adverse reactions to afatinib and their correlation with anti-lung cancer efficacy [J]. Chinese Journal of Dermatology, 2021, 54(1): 64-67.
[6]	Liu Hongwei, Hu Xueying, Lei Dongchun, Zhang Shoumin. Adalimumab in the treatment of severe plaque psoriasis: a clinical observation [J]. Chinese Journal of Dermatology, 2020, 53(9): 744-746.
[7]	Li Xin, Han Jianwen. Analysis of culprit drugs and screening for human leukocyte antigen genes in patients of Han nationality with Stevens-Johnson syndrome/toxic epidermal necrolysis in Inner Mongolia [J]. Chinese Journal of Dermatology, 2020, 53(9): 680-684.
[8]	Writing committee expert group on “diagnosis and treatment of psoriasis arthropathica: an expert consensus statement in China”. Diagnosis and treatment of psoriatic arthritis: an expert consensus statement in China（2020） [J]. Chinese Journal of Dermatology, 2020, 53(8): 585-595.
[9]	. Chinese expert consensus on β-blockers for the treatment of infantile hemangioma [J]. Chinese Journal of Dermatology, 2020, 53(7): 493-500.
[10]	Huaxia Skin Image and Artificial Intelligence Cooperation, China International Exchange and Promotion Association for Medical and Healthcare, Skin Imaging Group, Dermatology Branch of China International Exchange and Promotion Association for Medical and Healthcare, Skin Imaging Group, Committee on Dermatology and Venereology, Chinese Association of Integrative Medicine, Subcommittee on Dermatologic Surgery, China Dermatologist Association, Skin Imaging Group（preparing）, Chinese Society of Dermatology, Skin Imaging Equipment Group, Committee on Skin Disease and Cosmetic Dermatology, China Association of Medical Equipment. Consensus on dermoscopic characteristics of cutaneous malignant melanoma in China [J]. Chinese Journal of Dermatology, 2020, 53(6): 401-408.
[11]	Wang Yuan, Feng Suying. Drug-induced bullous pemphigoid [J]. Chinese Journal of Dermatology, 2020, 53(6): 487-489.
[12]	Chang Yuan, Chen Xixue, Wang Mingyue, Zhang Chenyang, Zhu Xuejun. Long-term effectiveness and safety of rituximab for the treatment of pemphigus [J]. Chinese Journal of Dermatology, 2020, 53(4): 279-284.
[13]	Committee on Allergic Diseases, China Dermatologist Association. Expert consensus on clinical application of patch test （2020 revised version） [J]. Chinese Journal of Dermatology, 2020, 53(4): 239-243.
[14]	Committee on Skin Disease Big Data, National Engineering Laboratory of Medical Big Data Application Technology （Central South University）, Center for Cancer Research, Chinese Society of Dermatology, Subcommittee on Skin Cancer, China Dermatologist Association. Expert consensus on the methodology of dermato-epidemiological investigations [J]. Chinese Journal of Dermatology, 2020, 53(12): 951-961.
[15]	Li Ming, Zhou Lihong, Li Linfeng. Prospects of Janus kinase inhibitors in the treatment of skin diseases [J]. Chinese Journal of Dermatology, 2020, 53(10): 845-848.

Expert consensus on the diagnosis and treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis

PDF

Like

Knowledge

Abstract

Cite this article

share this article

References ［53］

Related Articles 15

Metrics

Comments

Recommended 10